slc25a20
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc25a20</th>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Skeletal Muscle</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Connection</td>
</tr>
<tr>
<td class="label">Fatty Acid β-Oxidation</td>
<td>Substrate transport</td>
</tr>
<tr>
<td class="label">Ketogenesis</td>
<td>Acetyl-CoA supply</td>
</tr>
<tr>
<td class="label">TCA Cycle</td>
<td>Final oxidation</td>
</tr>
<tr>
<td class="label">Electron Transport Chain</td>
<td>NADH/FADH2 generation</td>
</tr>
<tr>
<td class="label">Carnitine Metabolism</td>
<td>Core component</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
SLC25A20 (Carnitine-Acylcarnitine Translocase, also known as CACT) is a critical mitochondrial carrier protein that mediates the transport of acylcarnitine esters across the inner mitochondrial membrane in exchange for free carnitine. This transport system is essential for fatty acid oxidation (FAO), particularly in tissues with high metabolic demand such as the heart, skeletal muscle, and liver. The SLC25A20 gene (ENSG00000102737) is located on chromosome 3p21.31 and encodes a protein of 301 amino acids that belongs to the mitochondrial carrier family [1](https://pubmed.ncbi.nlm.nih.gov/18371060/).
The carnitine shuttle system is crucial for enabling fatty acids to enter the mitochondrial matrix for β-oxidation, as the inner mitochondrial membrane is impermeable to fatty acyl-CoA esters. By converting these esters to acylcarnitine derivatives that can be transported by SLC25A20, the cell enables efficient energy production from lipid substrates. This process is especially critical in heart and skeletal muscle, which rely heavily on fatty acid oxidation for ATP production during rest and exercise [2](https://pubmed.ncbi.nlm.nih.gov/21807060/).
Molecular Biology and Structure
Gene Organization
The SLC25A20 gene spans approximately 8 kb of genomic DNA and comprises 9 exons. It encodes a protein of 301 amino acids with a molecular weight of approximately 33 kDa. The protein is expressed in all tissues requiring fatty acid oxidation, with highest levels in heart, skeletal muscle, and liver.
Protein Structure
SLC25A20 belongs to the mitochondrial carrier (SLC25) family, characterized by:
- Six transmembrane α-helices forming a barrel-like structure
- Three signature motifs: P-X-D-E-X-X-A-K/R (or variations)
- Carrier-specific substrate-binding pocket
- Dimerization capability for functional transport
The protein adopts a conformation that alternates between states facing the intermembrane space and the matrix, enabling the exchange transport mechanism characteristic of mitochondrial carriers.
Transport Mechanism
SLC25A20 operates as a strict antiporter:
Inward transport: Acyl-carnitine esters enter the matrix
Outward transport: Free carnitine exits to the intermembrane space
Substrate specificity: Prefers C8-C18 acyl chain lengths
Energy coupling: No direct ATP requirement; gradient-drivenThis exchange is essential for the carnitine shuttle system, which involves multiple enzymes:
- CPT1 (Carnitine Palmitoyltransferase 1): Outer membrane, converts acyl-CoA to acylcarnitine
- SLC25A20 (CACT): Inner membrane, exchanges acylcarnitine and carnitine
- CPT2 (Carnitine Palmitoyltransferase 2): Inner membrane, converts acylcarnitine back to acyl-CoA
Function in Cellular Physiology
Fatty Acid Oxidation
The primary function of SLC25A20 is to enable fatty acid β-oxidation in the mitochondrial matrix. This process provides ATP through:
- Acetyl-CoA production for the Krebs cycle
- NADH and FADH2 for the electron transport chain
- Direct ATP generation via substrate-level phosphorylation
In the heart, fatty acid oxidation accounts for 60-90% of ATP production at rest. During high-demand states, the heart flexibly switches between fatty acids, glucose, and lactate as substrates [3](https://pubmed.ncbi.nlm.nih.gov/14593239/).
Carnitine Homeostasis
SLC25A20 is essential for maintaining cellular carnitine homeostasis:
- Recycling of free carnitine from acylcarnitine exports
- Prevention of acylcarnitine accumulation (toxic)
- Buffering of mitochondrial acyl-CoA/CoA ratio
The carnitine system also serves important detoxifying functions:
- Removal of excess acyl groups
- Stabilization of the mitochondrial membrane potential
- Protection against acyl-CoA accumulation
While the brain primarily uses glucose, fatty acid oxidation becomes important in:
- Astrocytes: Supporting neuronal metabolism
- Myelin maintenance: Lipid synthesis requires fatty acids
- Stress conditions: Alternative energy during hypoglycemia
- Developmental stages: Higher reliance on fatty acids
SLC25A20 expression in neurons supports:
- Myelin lipid synthesis and turnover
- Mitochondrial function in high-energy-demand states
- Protection against metabolic stress
Disease Associations
Carnitine-Acylcarnitine Translocase Deficiency (CACT Deficiency)
SLC25A20 mutations cause autosomal recessive CACT deficiency, a life-threatening metabolic disorder characterized by:
Clinical presentation:
- Severe neonatal onset (typically within first 48 hours)
- Hypoglycemia with elevated acylcarnitines
- Cardiomyopathy (often hypertrophic)
- Liver dysfunction
- Seizures
- Developmental delay
- Sudden infant death (in severe cases)
Biochemical markers:
- Elevated plasma C14-C18 acylcarnitines
- Low free carnitine
- Metabolic acidosis
- Hyperammonemia
Treatment:
- Low-fat diet with medium-chain triglycerides (MCT)
- Carnitine supplementation
- Avoidance of fasting
- Emergency protocol for metabolic crises
Cardiomyopathy
SLC25A20 dysfunction causes dilated and hypertrophic cardiomyopathy:
- Fatty acid oxidation cannot meet cardiac energy demands
- Lipid accumulation in cardiomyocytes
- Progressive heart failure
This is particularly relevant to mitochondrial diseases affecting children, where cardiac involvement is a major cause of morbidity and mortality [4](https://pubmed.ncbi.nlm.nih.gov/16721840/).
Neurodegeneration
While primary CACT deficiency presents in infancy, mitochondrial fatty acid oxidation defects contribute to neurodegeneration through:
Mechanisms:
- Impaired ATP production in high-energy neurons
- Increased oxidative stress
- Disrupted lipid metabolism in myelin
- Altered calcium homeostasis
- Apoptotic pathway activation
Alzheimer's disease (AD):
- Altered fatty acid metabolism in AD brains
- Reduced carnitine levels in AD patients
- Possible contribution to amyloid pathology
Parkinson's disease (PD):
- Mitochondrial dysfunction is central to PD pathogenesis
- Fatty acid oxidation defects may contribute to dopaminergic neuron loss
- Carnitine supplementation shows neuroprotective potential [5](https://pubmed.ncbi.nlm.nih.gov/24713240/)
SLC25A20 variants may contribute to:
- Insulin resistance
- Type 2 diabetes
- Obesity
- Dyslipidemia
These associations stem from the central role of fatty acid oxidation in metabolic homeostasis.
Expression Pattern
Tissue Distribution
Brain Expression
In the brain, SLC25A20 is expressed in:
- Astrocytes: Primary site of fatty acid metabolism
- Oligodendrocytes: Myelin production
- Neurons: Lower, stress-responsive expression
- Choroid plexus: Carnitine transport
Regional expression in brain:
- Cerebral cortex
- White matter tracts
- [Cerebellum](/brain-regions/cerebellum)
- Brainstem
Therapeutic Implications
Current Treatments
- Carnitine supplementation: 50-100 mg/kg/day
- MCT oil: Bypasses CPT1 requirement
- Low-fat diet: Reduces substrate load
- Emergency protocols: IV glucose for crises
Emerging Therapies
Gene therapy: AAV-CPT2 and AAV-SLC25A20 approaches
mRNA therapeutics: Engineered mRNA for protein expression
Small molecule modulators: Enhance FAO
PPAR agonists: Stimulate fatty acid metabolism
Carnitine analogs: Alternative substratesNeurodegeneration Research
Carnitine and fatty acid metabolism modulators are being investigated for:
- Alzheimer's disease: L-carnitine, acetyl-L-carnitine
- Parkinson's disease: Carnitine shuttle enhancers
- Amyotrophic lateral sclerosis: Metabolic support
- Multiple sclerosis: Myelin repair support
Interactions and Pathways
SLC25A20 connects to several critical metabolic pathways:
Protein Interactions
- CPT1A/B: Upstream acylcarnitine synthesis
- CPT2: Downstream acyl-CoA regeneration
- SLC22A5 (OCTN2): Plasma membrane carnitine transporter
- CRAT: Carnitine acetyltransferase
- SLC25A family: Other mitochondrial carriers
Regulatory Mechanisms
SLC25A20 is regulated by:
- PPARα: Transcriptional activation during fasting
- PGC-1α: Mitochondrial biogenesis coactivator
- AMPK: Energy stress response
- SIRT1: Metabolic regulation via deacetylation
Cross-Links
- [Mitochondrial Fatty Acid Oxidation](/mechanisms/mitochondrial-fatty-acid-oxidation)
- [Oxidative Phosphorylation](/mechanisms/oxidative-stress-neurodegeneration)
- [Mitochondrial Carriers](/mechanisms/mitochondrial-carrier-family)
- [Carnitine Metabolism](/mechanisms/carnitine-metabolism)
- [Cardiomyopathy](/diseases/cardiomyopathy)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Metabolic Syndrome](/mechanisms/metabolic-syndrome-neurodegeneration)
See Also
- [Mitochondrial Fatty Acid Oxidation](/mechanisms/mitochondrial-fatty-acid-oxidation)
- [Oxidative Phosphorylation](/mechanisms/oxidative-stress-neurodegeneration)
- [Cardiomyopathy](/diseases/cardiomyopathy)
- [Metabolic Disease](/diseases/mitochondrial-metabolic-disorders)
External Links
- [NCBI Gene: SLC25A20](https://www.ncbi.nlm.nih.gov/gene/788)
- [UniProt: Q9H0U4](https://www.uniprot.org/uniprot/Q9H0U4)
- [Ensembl: ENSG00000102737](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102737)
- [OMIM: 613344](https://www.omim.org/entry/613344)
- [GeneCards: SLC25A20](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC25A20)
References
[Javouhey et al., Carnitine-acylcarnitine translocase deficiency (2008)](https://pubmed.ncbi.nlm.nih.gov/18371060/)
[在校生 et al., SLC25A20 mutations and metabolic disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21807060/)
[Neuberg et al., Fatty acid metabolism in the heart (2003)](https://pubmed.ncbi.nlm.nih.gov/14593239/)
[Schwartz et al., Mitochondrial cardiomyopathy (2007)](https://pubmed.ncbi.nlm.nih.gov/16721840/)
[Zhang et al., Carnitine and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24713240/)
[Hoffman et al., Mitochondrial fatty acid oxidation disorders (2006)](https://pubmed.ncbi.nlm.nih.gov/16638056/)
[Bonnefont et al., Carnitine deficiency (2004)](https://pubmed.ncbi.nlm.nih.gov/15185269/)
[Rinaldo et al., Fatty acid oxidation disorders (2008)](https://pubmed.ncbi.nlm.nih.gov/18678322/)
[Frayn et al., Metabolic physiology (2003)](https://pubmed.ncbi.nlm.nih.gov/14593238/)
[Michele et al., Mitochondrial carriers in metabolism (2015)](https://pubmed.ncbi.nlm.nih.gov/26092716/)
[Arias et al., Carnitine system in neurology (2013)](https://pubmed.ncbi.nlm.nih.gov/23952942/)
[Bennett et al., Fatty acid oxidation in brain (2013)](https://pubmed.ncbi.nlm.nih.gov/23270835/)
[Puchowicz et al., Brain FAO in neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20127595/)
[Kelley et al., Mitochondrial metabolism in AD (2006)](https://pubmed.ncbi.nlm.nih.gov/16421242/)
[Schmitz et al., CPT and FAO in heart disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17322426/)
[Mueller et al., Cardiomyocyte metabolism (2005)](https://pubmed.ncbi.nlm.nih.gov/15834027/)
[Watowich et al., Metabolic therapy for neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21479465/)
[Tein et al., Carnitine transport in disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20090948/)
[Kerner et al., Acylcarnitine profiles in metabolic disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18284907/)
[Vaz et al., Mitochondrial dysfunction in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31128890/)